BNGO vs MBAI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.
MBAI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical lack of revenue. The company has reported losses for 25 consecutive quarters, with a devastating ROE of -130.12% and a Current Ratio of 0.71, indicating an inability to cover short-term liabilities. While the 1-year price performance shows a speculative rally, the underlying fundamentals are non-existent, and the absence of an Altman Z-Score or Graham Number reflects a lack of stable equity or earnings to support a valuation.
Compare Another Pair
Related Comparisons
BNGO vs MBAI: Head-to-Head Comparison
This page compares Bionano Genomics, Inc. (BNGO) and Check-Cap Ltd. (MBAI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.